# Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

> **NCT07308886** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (estimated)

## Conditions studied

- Kaposi Sarcoma

## Interventions

- **DRUG:** CYT107

## Key facts

- **NCT ID:** NCT07308886
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2036-01-31
- **Final completion:** 2037-01-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07308886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07308886, "Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT07308886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*